POAG puts pressure on the heart

Article

Patients with primary open-angle glaucoma (POAG) have a higher level of cardiovascular risk than in age-matched patients without glaucoma, according to a report published in a recent issue of Graefe's Archive for Clinical and Experimental Ophthalmology.

Patients with primary open-angle glaucoma (POAG) have a higher level of cardiovascular risk than in age-matched patients without glaucoma, according to a report published in a recent issue of Graefe's Archive for Clinical and Experimental Ophthalmology.

Nicola Orzalesi and colleagues from the OPTIME Study group, collected and analysed data from the medical history of 2,879 POAG patients and 973 age-matched controls, from 35 centres in Italy. Data relating to vascular risk factors were collected by means of a detailed questionnaire and all subjects underwent a complete ophthalmic examination with assessment of intraocular pressure (IOP), visual field, optic disc and systemic blood pressure. The European Society of Hypertension/European Society of Cardiology (ESH-ESC) guidelines were used to calculate the level of cardiovascular risk.

The POAG patients had significantly higher systolic and diastolic blood pressure, systolic perfusion pressure and IOP compared to the control group. However, diastolic perfusion pressure did not significantly differ between the groups. Myopia was more common in the POAG group (23% compared to 18%), as was a positive family history of glaucoma (26% compared to 12%). POAG patients also tended to have a higher cardiovascular risk than controls. A total of 63% of POAG patients and 55% of controls had a high or very high cardiovascular risk.

The authors found that patients with POAG do have a greater cardiovascular risk than those who do not have glaucoma.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.